- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT05539859
Effekt og sikkerhet ved nevroendoskopisk kirurgi for intracerebral blødning (NESICH)
Effekt og sikkerhet ved nevroendoskopisk kirurgi for intracerebral blødning: en randomisert, kontrollert, åpen, blindet endepunktforsøk
To compare the efficacy and safety of neuroendoscopic hematoma removal and standard conservative treatment for patients with spontaneous supratentorial deep intracerebral hemorrhage.
Studieoversikt
Status
Intervensjon / Behandling
Detaljert beskrivelse
Neuroendoscopic treatment of spontaneous intracerebral hemorrhage (ICH) is more and more widely used, but multi-center clinical study on the efficacy and safety of neuroendoscopic treatment of ICH is relatively small. Based on the lack of sufficient clinical evidence, the investigators plan to conduct a prospective, multicenter, randomized controlled clinical trial to investigate the safety and efficacy of neuroendoscopy in the treatment of spontaneous cerebral parenchymal hemorrhage, so as to provide evidence-based medical evidence for endoscopic minimally invasive treatment of cerebral hemorrhage and its application.The aim of trial was to determine whether the endoscopic surgery could achieve the benefits of clot evacuation and improve functional outcome at 180 days after ICH without procedure-related safety events or additional brain injury beyond the risks associated with standard care
Studietype
Registrering (Antatt)
Fase
- Ikke aktuelt
Kontakter og plasseringer
Studiekontakt
- Navn: Rong Hu, MD
- Telefonnummer: 8615123917123
- E-post: huchrong@aliyun.com
Studer Kontakt Backup
- Navn: Hua Feng, MD
- Telefonnummer: 8613708321681
- E-post: fenghua201818@aliyun.com
Studiesteder
-
-
-
Ganzhou, Kina
- Rekruttering
- Ganzhou city people's Hospita
-
Ta kontakt med:
- Yun X Ye, MD
-
-
Chongqing Municipality
-
Chongqing, Chongqing Municipality, Kina, 400014
- Rekruttering
- chongqing Emergency Medical Center
-
Ta kontakt med:
- Bing y Deng, MD
-
-
Hubei
-
Hubei, Hubei, Kina, 441000
- Rekruttering
- Xiang Yang NO.1 Peoples Hospital
-
Ta kontakt med:
- Hua Cu Fu, MD
- Telefonnummer: 15172552710
- E-post: nianbeifch@163.com
-
-
Sichuan
-
Sichuan, Sichuan, Kina, 635100
- Rekruttering
- Dazhu County People's Hospital
-
Hovedetterforsker:
- sheng zhu, MD PHD
-
Ta kontakt med:
- sheng zhu, MD
- Telefonnummer: +8615882911301
- E-post: 371773434@qq.com
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Age 18-80 years, either sex.
- Time from onset to the first diagnostic CT within 24 hours (for those without bystanders and with unknown onset time, use the last known time the patient was in good condition)
- Deep (external capsule, putamen, internal capsule, caudate nucleus) supratentorial cerebral hemorrhage with a hematoma volume ≥ 25 ml.
- Stability of the hematoma determined by two CT scans at different times after onset. If the hematoma enlarges 5ml then the stability of the hematoma can be detected by CT again after 6 hours until the randomization time window is closed.
- Pre-randomization GCS score of 5-14 and/or NIHSS score of ≥6.
- Pre-onset Modified Rankin Scale (mRS) score 0 or 1.
- Blood pressure recorded 6 hours prior to randomization consistently controlled at 180 mmHg or less.
- Randomization completed within 24 hours after the first diagnostic CT, and surgical intervention should be performed as soon as possible, no later than 6 hours after randomization, that is to say, surgery should be performed no later than 54 hours after onset.
- Informed and voluntarily signed informed consent by the patient or family.
Exclusion Criteria:
- Hemorrhage clinically diagnosed as a result of cerebral aneurysm, cerebrovascular malformation, moyamoya disease, traumatic brain injury, brain tumor, hemorrhagic transformation of a large cerebral infarct, coagulation dysfunction.
- Lobar hemorrhages, thalamic hemorrhages, primary ventricular hemorrhages, cerebellum hemorrhages and brain stem hemorrhages.
- Hematoma involving the midbrain, with dilated or unresponsive pupils.
- Hematoma producing life-threatening occupying effects (e.g., CT showing midline deviation of more than 1 cm, loss of cisterna ambiens) or patients who are extremely unstable and unfit for enrollment.
- Platelet count <100×10^9/L, international normalized ratio (INR) >1.4.
- Hematoma extension to ventricle and completely blocked the third or fourth ventricle.
- Recent history of cerebral hemorrhage (less than 1 year).
- Severe hepatic impairment with ALT 3 times the upper limit of normal, or AST 3 times the upper limit of normal. Severe renal insufficiency with glomerular filtration rate less than 30 ml/min/1.73 m2.
- Blood pressure not effectively controlled to less than 180 mmHg despite aggressive antihypertensive therapy prior to randomization.
- Patients with severe advanced cognitive impairment (e.g. AD) or psychiatric disorders who are unable to complete the follow-up program as required.
- Comorbid other serious diseases such as respiratory, circulatory, digestive, urological, endocrine, immune and hematologic disorders.
- Pregnant or lactating women, or those who expect to become pregnant within one year.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Enkelt
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: Experimental Arm
Endoscopic surgery |
Subjects will receive surgical hematoma evacuation using neuroendoscope, followed by medical management |
|
Aktiv komparator: Control Arm
Medical management |
Subjects will initially receive the standard medical therapies for the treatment of intracerebral hemorrhage, according to the latest available guideline. |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
The proportion of patients with Modified Rankin Scale (mRS) score 0-3
Tidsramme: 180 days
|
Functional outcome (comparing the intervention group to the control), assessed with the modified Rankin Scale (mRS) at 6 months.The mRS is a commonly used scale for measuring the degree of disability or dependence in the daily activities of people who have suffered a stroke or other causes of neurological disability. It is scored from: 0=No symptoms at all, 1=No significant disability, 2=Slight disability, 3=Moderate disability, 4=Moderately severe disability, 5=Severe disability and 6=death. |
180 days
|
|
Safety outcome
Tidsramme: 180 days
|
All cause mortality from onset to 180 days |
180 days
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Glasgow Outcome Scale Extended (GOS-E)
Tidsramme: 30 days.
|
GOS-E subdivides the categories of severe and moderate disability and good recovery using a scale of 1 to 8 where 1 = death, 2 = vegetative state, 3 = lower severe disability, 4 = upper severe disability, 5 = lower moderate disability, 6 = upper moderate disability, 7 = lower good recovery, and 8 = upper good recovery. Structured telephone interviews have been developed and validated for the GOS-E and these questions were incorporated into the follow-up survey. GOS-E was dichotomized into unfavorable (1 to 4) and favorable (5 to 8) outcomes. |
30 days.
|
|
Glasgow Outcome Scale Extended (GOS-E)
Tidsramme: 90 days.
|
GOS-E subdivides the categories of severe and moderate disability and good recovery using a scale of 1 to 8 where 1 = death, 2 = vegetative state, 3 = lower severe disability, 4 = upper severe disability, 5 = lower moderate disability, 6 = upper moderate disability, 7 = lower good recovery, and 8 = upper good recovery. Structured telephone interviews have been developed and validated for the GOS-E and these questions were incorporated into the follow-up survey. GOS-E was dichotomized into unfavorable (1 to 4) and favorable (5 to 8) outcomes. |
90 days.
|
|
Glasgow Outcome Scale Extended (GOS-E)
Tidsramme: 180 days.
|
GOS-E subdivides the categories of severe and moderate disability and good recovery using a scale of 1 to 8 where 1 = death, 2 = vegetative state, 3 = lower severe disability, 4 = upper severe disability, 5 = lower moderate disability, 6 = upper moderate disability, 7 = lower good recovery, and 8 = upper good recovery. Structured telephone interviews have been developed and validated for the GOS-E and these questions were incorporated into the follow-up survey. GOS-E was dichotomized into unfavorable (1 to 4) and favorable (5 to 8) outcomes. |
180 days.
|
|
Modified Rankin Scale (mRS) Score
Tidsramme: 30 days.
|
The mRS is a commonly used scale for measuring the degree of disability or dependence in the daily activities of people who have suffered a stroke or other causes of neurological disability. It is scored from: 0=No symptoms at all, 1=No significant disability, 2=Slight disability, 3=Moderate disability, 4=Moderately severe disability, 5=Severe disability and 6=death. |
30 days.
|
|
Modified Rankin Scale (mRS) Score
Tidsramme: 90 days .
|
The mRS is a commonly used scale for measuring the degree of disability or dependence in the daily activities of people who have suffered a stroke or other causes of neurological disability. It is scored from: 0=No symptoms at all, 1=No significant disability, 2=Slight disability, 3=Moderate disability, 4=Moderately severe disability, 5=Severe disability and 6=death. |
90 days .
|
|
Survival rate
Tidsramme: 30 days.
|
comparing the intervention group to the control |
30 days.
|
|
Survival rate
Tidsramme: 90 days.
|
comparing the intervention group to the control |
90 days.
|
|
Assessment of cognitive function with Mini-Mental State Examination (MMSE)
Tidsramme: 30 days.
|
The MMSE is a screening test for cognitive dysfunction. The test consists of five sections (orientation, registration, attention-calculation, recall, and language); the total score can range from 0 to 30, with a higher score indicating better function. |
30 days.
|
|
Assessment of cognitive function with Mini-Mental State Examination (MMSE)
Tidsramme: 90 days.
|
The MMSE is a screening test for cognitive dysfunction. The test consists of five sections (orientation, registration, attention-calculation, recall, and language); the total score can range from 0 to 30, with a higher score indicating better function. |
90 days.
|
|
Assessment of cognitive function with Mini-Mental State Examination (MMSE)
Tidsramme: 180 days.
|
The MMSE is a screening test for cognitive dysfunction. The test consists of five sections (orientation, registration, attention-calculation, recall, and language); the total score can range from 0 to 30, with a higher score indicating better function. |
180 days.
|
|
Quality of life measured with the 5-level EQ-5D (EQ-5D-5L)
Tidsramme: 30 days.
|
The EQ-5D-5L is a standard measure of health-related quality of life.EQ-5D-5L consists of two components: a health state profile and a visual analog scale (VAS). EQ-5D health state profile comprises 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has 5 levels: 1=no problems, 2=slight problems, 3=moderate problems, 4=severe problems, and 5=extreme problems. The 5D-5L systems are converted into a single index utility score between 0 to 1, where a higher score indicates a better health state. The VAS records the participant's health on a 0-100 mm VAS scale, with 0 indicating "the worst health you can imagine" and 100 indicating "the best health you can imagine". Higher scores of EQ VAS indicate better health. |
30 days.
|
|
Quality of life measured with the 5-level EQ-5D (EQ-5D-5L)
Tidsramme: 90 days.
|
The EQ-5D-5L is a standard measure of health-related quality of life.EQ-5D-5L consists of two components: a health state profile and a visual analog scale (VAS). EQ-5D health state profile comprises 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has 5 levels: 1=no problems, 2=slight problems, 3=moderate problems, 4=severe problems, and 5=extreme problems. The 5D-5L systems are converted into a single index utility score between 0 to 1, where a higher score indicates a better health state. The VAS records the participant's health on a 0-100 mm VAS scale, with 0 indicating "the worst health you can imagine" and 100 indicating "the best health you can imagine". Higher scores of EQ VAS indicate better health. |
90 days.
|
|
Quality of life measured with the 5-level EQ-5D (EQ-5D-5L)
Tidsramme: 180 days.
|
The EQ-5D-5L is a standard measure of health-related quality of life.EQ-5D-5L consists of two components: a health state profile and a visual analog scale (VAS). EQ-5D health state profile comprises 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has 5 levels: 1=no problems, 2=slight problems, 3=moderate problems, 4=severe problems, and 5=extreme problems. The 5D-5L systems are converted into a single index utility score between 0 to 1, where a higher score indicates a better health state. The VAS records the participant's health on a 0-100 mm VAS scale, with 0 indicating "the worst health you can imagine" and 100 indicating "the best health you can imagine". Higher scores of EQ VAS indicate better health. |
180 days.
|
|
Length of ICU
Tidsramme: Number of days from admission, up to 180 days
|
Duration of stay in the ICU |
Number of days from admission, up to 180 days
|
|
Length of hospitalization
Tidsramme: Number of days from admission to discharge, up to 180 days
|
Duration of stay in the hospital |
Number of days from admission to discharge, up to 180 days
|
|
In-hospital cost
Tidsramme: Number of days from admission to discharge, up to 180 days
|
all medical cost during the in-hospital period |
Number of days from admission to discharge, up to 180 days
|
Samarbeidspartnere og etterforskere
Sponsor
Etterforskere
- Studiestol: Rong Hu, MD, PLA Army Medical University
Publikasjoner og nyttige lenker
Generelle publikasjoner
- Hansen BM, Ullman N, Muschelli J, Norrving B, Dlugash R, Avadhani R, Awad I, Zuccarello M, Ziai WC, Hanley DF, Thompson RE, Lindgren A; MISTIE and CLEAR Investigators. Relationship of White Matter Lesions with Intracerebral Hemorrhage Expansion and Functional Outcome: MISTIE II and CLEAR III. Neurocrit Care. 2020 Oct;33(2):516-524. doi: 10.1007/s12028-020-00916-4.
- de Oliveira Manoel AL. Surgery for spontaneous intracerebral hemorrhage. Crit Care. 2020 Feb 7;24(1):45. doi: 10.1186/s13054-020-2749-2.
- Anderson CD, James ML. Survival and independence after intracerebral hemorrhage: Trends and opportunities. Neurology. 2018 Jun 5;90(23):1043-1044. doi: 10.1212/WNL.0000000000005625. Epub 2018 May 4. No abstract available.
- Kuo LT, Chen CM, Li CH, Tsai JC, Chiu HC, Liu LC, Tu YK, Huang AP. Early endoscope-assisted hematoma evacuation in patients with supratentorial intracerebral hemorrhage: case selection, surgical technique, and long-term results. Neurosurg Focus. 2011 Apr;30(4):E9. doi: 10.3171/2011.2.FOCUS10313.
- Kellner CP, Song R, Pan J, Nistal DA, Scaggiante J, Chartrain AG, Rumsey J, Hom D, Dangayach N, Swarup R, Tuhrim S, Ghatan S, Bederson JB, Mocco J. Long-term functional outcome following minimally invasive endoscopic intracerebral hemorrhage evacuation. J Neurointerv Surg. 2020 May;12(5):489-494. doi: 10.1136/neurintsurg-2019-015528. Epub 2020 Jan 8.
- Xu X, Chen X, Li F, Zheng X, Wang Q, Sun G, Zhang J, Xu B. Erratum. Effectiveness of endoscopic surgery for supratentorial hypertensive intracerebral hemorrhage: a comparison with craniotomy. J Neurosurg. 2018 Feb;128(2):649. doi: 10.3171/2017.5.JNS161589a. Epub 2017 Jul 28. No abstract available.
- Wang L, Zhou T, Wang P, Zhang S, Yin Y, Chen L, Duan H, Wu N, Feng H, Hu R. Efficacy and safety of NeuroEndoscopic Surgery for IntraCerebral Hemorrhage: A randomized, controlled, open-label, blinded endpoint trial (NESICH). Int J Stroke. 2024 Jun;19(5):587-592. doi: 10.1177/17474930241232292. Epub 2024 Feb 19.
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
- Cerebrovaskulære lidelser
- Hjernesykdommer
- Sykdommer i sentralnervesystemet
- Sykdommer i nervesystemet
- Vaskulære sykdommer
- Kardiovaskulære sykdommer
- Patologiske prosesser
- Blødning
- Intrakranielle blødninger
- Patologiske tilstander, tegn og symptomer
- Hjerneblødning
- Profesjonell praksis
- Organisasjon og administrasjon
- Health Services Administration
- Diagnostiske teknikker og prosedyrer
- Diagnose
- Kirurgiske prosedyrer, operativ
- Minimalt invasive kirurgiske inngrep
- Diagnostiske teknikker, kirurgisk
- Praksisadministrasjon
- Endoskopi
- Øvelsesledelse, medisinsk
Andre studie-ID-numre
- (A)KY2022103
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .